Stock Evaluator: IGC Pharma, Inc. (IGC)

IGC Pharma, Inc. IGC

$0.25 0.00 -0.20%
July 31, 2026 4:00:00 PM EST November 10, 2021 Volume: 168,688
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD AMEX | DELAYED PRICE
SECTOR INDUSTRY
Health Care Pharmaceuticals

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer’s disease in the United States and Colombia. The company’s lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer’s. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer’s disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.

Commentary & Analysis


Financial Summary

Share Statistics IGC Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $25.0 $569.9 12%
Shares Out (Mil) 98.2 44.8 62%
Institutional Ownership 57.3% 84.6% 38%
Float (Mil) 86.1 45.1 58%
Beta 0.45 0.67 25%
Avg Daily Volume (000s) 323 294 52%
Price Change
(52-week)
(32.6%) 65.2% 23%
Growth IGC Industry
Median
Percentile
(All Stocks)
Sales (5yr) (20.5%) 6.7% 2%
Net Income (5yr) 0.6% (2.0%) 40%
EPS (5yr) 12.9% 14.9% 52
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) 53.5% (14.9%) 94%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 2 1 na
Current EPS ($0.020) ($0.090) na
Month Ago EPS ($0.020) ($0.090) na
# Rev Up na 0 na
# Rev Down na 1 na
Three Months Ago EPS ($0.020) ($0.090) na
Year/Year Chg (16.7%) (3.2%) (8.6%)
Financials IGC Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $1 $230 2%
Net Income (TTM) (Mil) ($6) ($11) 32%
EPS (TTM) ($0.078) ($0.600) 37%
Operating Cash Flow (TTM) (Mil) ($6) ($6) 24%
Net Cash Flow (TTM) (Mil) $-0 $4 43%
Long-Term Debt (Q1) (Mil) $0 $7 12%
Enterprise Value (Q1) (Mil) $27 $493 12%
Valuation IGC Industry
Median
Percentile
(All Stocks)
P/B 4.16 2.89 74%
P/E na 20.6 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 1.1 na
Ratios IGC Industry
Median
Percentile
(All Stocks)
Gross Margin 46.2% 65.9% 58%
Net Margin (582.8%) (0.2%) 1%
ROA (71.9%) (25.5%) 8%
ROE (103.5%) (21.4%) 9%
Liabilities to Assets 33.4% 35.5% 24%
F-Score 2 3 7%

IGC Pharma, Inc. did not pass any screens on 7/30/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors